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Retroviruses are associated with a wide variety of diseases, including immunological, neu-
rological disorders, and different forms of cancer. Among retroviruses, Oncovirinae regroup
according to their genetic structure and sequence, several related viruses such as human
T-cell lymphotropic viruses types 1 and 2 (HTLV-1 and HTLV-2), simian T cell lymphotropic
viruses types 1 and 2 (STLV-1 and STLV-2), and bovine leukemia virus (BLV). As in many
diseases, animal models provide a useful tool for the studies of pathogenesis, treatment,
and prevention. In the current review, an overview on different animal models used in the
study of these viruses will be provided. A speciﬁc attention will be given to the HTLV-1 virus
which is the causative agent of adult T-cell leukemia/lymphoma (ATL) but also of a num-
ber of inﬂammatory diseases regrouping the HTLV-associated myelopathy/tropical spastic
paraparesis (HAM/TSP), infective dermatitis and some lung inﬂammatory diseases. Among
thesemodels, rabbits, monkeys but also rats provide an excellent in vivo tool for early HTLV-
1 viral infection and transmission as well as the induced host immune response against
the virus. But ideally, mice remain the most efﬁcient method of studying human afﬂictions.
Genetically alteredmice including both transgenic and knockoutmice, offer important mod-
els to test the role of speciﬁc viral and host genes in the development of HTLV-1-associated
leukemia. The development of different strains of immunodeﬁcient mice strains (SCID,
NOD, and NOG SCID mice) provide a useful and rapid tool of humanized and xenografted
mice models, to test new drugs and targeted therapy against HTLV-1-associated leukemia,
to identify leukemia stem cells candidates but also to study the innate immunity mediated
by the virus. All together, these animal models have revolutionized the biology of retro-
viruses, their manipulation of host genes and more importantly the potential ways to either
prevent their infection or to treat their associated diseases.
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INTRODUCTION
The family Retroviridae is composed of numerous non-
icosahedral, enveloped viruses that possess two copies of a
single-stranded RNA genome. The Retroviridae have two deﬁning
hallmarks of replication: the reverse transcription of the genomic
RNA into a linear double-stranded DNA copy and the subsequent
covalent integration of this DNA into the host genome. Among
retroviruses, the Oncovirus family regroups many viruses hav-
ing a clinical, economical, and veterinary signiﬁcance. Human
T-cell lymphotropic virus (HTLV)-1 belongs to the Delta-type
retroviruses, which also include HTLV-2, -3, and -4, simian T-cell
leukemia viruses STLV-1, -2, -3, -4, and -5, and bovine leukemia
virus (BLV; Table 1). Animal models provide an excellent tool
to understand the biology of oncoviruses related diseases, and to
develop vaccines or targeted therapies. These animal models vary
from naturally infected hosts to established or engineered animal
models that mimic the related disease in patients (Table 1).
NATURALLY INFECTED HOSTS
BOVINE LEUKEMIA VIRUS
The symptoms of BLV were ﬁrst discovered in 1871 when Leiser-
ing reported the occurrence in cattle of a disease called “leukosis”
leading to splenomegaly associated with yellowish nodules in
spleens of infected cows (Leisering, 1871). This spleen disruption
is consecutive to tumor formation and is the most spectacular
clinical manifestation in BLV infected cattle. Tumors result from
accumulation of transformed B cells in the spleen as well as diverse
organ inﬁltration of the liver, heart, eye, skin, lung, and lymph
nodes (reviewed in Burny et al., 1987; Olson and Miller, 1987;
Willems et al., 1999; Meas et al., 2002). This fatal lymphoma or
lymphosarcoma occurs in <5–10% of infected animals, predomi-
nantly adult cattle older than 4–5 years (Ferrer, 1980; Burny et al.,
1985,1988)whereas the greatmajority of infected animals (around
70%) remain asymptomatic carriers of the virus. These animals
can only be identiﬁed by the presence of anti-BLV antibodies
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Table 1 | BLV and PTLV: related hosts, diseases, and animal models.
Virus Host Disease Animal models
Bovine leukemia virus (BLV) Cattle Leukosis - Sheep
- Rats
- Rabbits
HumanT-cell leukemia virus (HTLV-1) Humans - Adult T cell leukemia/lymphoma (ATL)
- HTLV-1-associated myelopathy/tropical spastic
paraparesis (HAM/TSP)
- Infective dermatitis
- Ocular lesions
- Inﬂammatory arthropathy and polymyositis
- Primates
- Rabbits
- Rats
- Mice models (xenografts,
humanized, transgenics).
SimianT-cell leukemia virus (STLV) Non-human primates Unknown Non-human primates
and/or of proviral DNA (Kettmann et al., 1976; Burny et al., 1988;
Kettmann and Burny, 1994). In these settings, <1 % of periph-
eral blood cells in animals are found to be infected by the virus
(reviewed inGillet et al., 2007). BLV can be transmitted though the
milk horizontally (Ferrer and Piper, 1978). Nowadays, BLV causes
major economical losses in cattle production and export (Trono
et al., 2001; Motton and Buehring, 2003; Ott et al., 2003; Rhodes
et al., 2003).
PRIMATE T-CELL LYMPHOTROPIC VIRUSES: HUMAN T-CELL LEUKEMIA
VIRUS AND SIMIAN T-CELL LEUKEMIA VIRUS
The primate T-cell lymphotropic viruses (PTLV) regroup the
HTLVs (HTLV-1, -2, -3, and -4) as well as their related simian
counterparts STLV-1, -2, and -3 (Lairmore and Franchini, 2007).
Two additional STLV (-4 and -5) belong also to PTLVs but have no
human counterparts discovered to date. While PTLV-1 and PTLV-
2 strains have been extensively studied since the 1980s, studies on
PTLV-3 are more recent and have increased in number since the
discovery of HTLV-3 in 2005 (Calattini et al., 2005; Wolfe et al.,
2005). HTLV-4, the fourth human HTLV retrovirus, was also dis-
covered in 2005, but a simian counterpart of this virus has not
been identiﬁed to date (Wolfe et al., 2005; Sintasath et al., 2009).
Simian T-cell leukemia viruses
The high percentage of homologies between HTLV and STLV
strains, led to the demonstration that most HTLV subtypes arose
from interspecies transmission between monkeys and humans.
STLVs have been documented in more than 30 non-human pri-
mate (NHP) species from sub-Saharan Africa and Asia (Locatelli
and Peeters, 2012). STLV-1 has been documented in captive but
wild-caught chimpanzees and gorillas from west Central Africa
(Gessain and Mahieux, 2000; Nerrienet et al., 2004). STLV-2 has
only been documented in bonobos, an ape species endemic to
Democratic Republic of Congo (Van Brussel et al., 1998). The
ﬁrst strain of STLV-3 was isolated in 1994, after the long-term
co-culture of human cord blood lymphocytes with the peripheral
blood mononuclear cells (PBMCs), obtained from an Eritrean
sacred baboon that had been kept in captivity in a research
laboratory in Leuven, Belgium (Goubau et al., 1994). Sequence
comparisons of STLV-3 full-length proviruses pointed out that
these strains are highly divergent from HTLV-1, HTLV-2, or
STLV-2 prototype sequences (around 40% nucleotide divergence;
Meertens et al., 2002, 2003; Meertens and Gessain, 2003).
Human T-cell leukemia viruses
HTLV-1 is the ﬁrst human retrovirus discovered, and is the etiolog-
ical agent of twodistinct diseases: adult T-cell leukemia/lymphoma
(ATL; Poiesz et al., 1980; Hinuma et al., 1981, 1982; Yoshida
et al., 1982) and tropical spastic paraparesis/HTLV-1-associated
myelopathy (TSP/HAM). ATL is an aggressive malignancy of
mature activated CD4+ T cells, characterized by frequent visceral
involvement, malignant hypercalcemia and opportunistic infec-
tions secondary to T cell immunosuppression. TSP/HAM is a
slowly progressive neurodegenerative disorder in which lesions
in the central nervous system (CNS) cause progressive weakness,
stiffness, and a lower limb spastic paraparesis leading to the paral-
ysis of the legs (Gessain et al., 1985; Rodgers-Johnson et al., 1985;
Osame, 1986).
HTLV-1 infects approximately 20 million individuals world-
wide (Matsuoka, 2003). Endemic areas include Japan, the
Caribbean, inter-tropical Africa, Brazil, Eastern Europe, and the
Middle East (Kaplan and Khabbaz, 1993; Abbaszadegan et al.,
2003; Nagai and Osame, 2003). ATL develops in a small percentage
(4%) of HTLV-1-infected individuals after a long period of clini-
cal latency (20–40 years following viral infection; Hermine et al.,
1998; Bazarbachi and Hermine, 2001; Bazarbachi et al., 2004). Yet,
ATL is characterized by the monoclonal integration of HTLV-1
provirus in the tumor cells (Yoshida et al., 1984). Typical ATL cells
are characterized by unusual morphology with lobulated nucleus,
known as“ﬂower cells” (Shimoyama et al., 1983). These malignant
lymphocytes are activated CD4+ T cells with increased expression
of the alpha chain of the interleukin (IL)-2 receptor (Waldmann
et al., 1985; Okayama et al., 1997).
In addition to the classical structural genes required for retrovi-
ral replication, the HTLV-1 genome encodes a series of accessory
and regulatory proteins (Figure 1A) such as the viral transcrip-
tional activator Tax (Slamon et al., 1984) and the HTLV-1 bZIP
factor gene (HBZ), a recently discovered unique viral protein
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FIGURE 1 | (A) HTLV-1 proviral genone. (B) BLV-1 proviral genome.
encoded from the 3′ LTR in the complementary strand of the
proviral genome (Gaudray et al., 2002). Both Tax and HBZ were
shown to be linked to HTLV-1 pathogenesis (Boxus and Willems,
2009; Kannian and Green, 2010).
The diversity in prognosis and clinical features of patients
with ATL led to the Shimoyama classiﬁcation of this disease into
four clinical subtypes: acute, lymphoma, chronic, and smolder-
ing forms (Shimoyama, 1991). This classiﬁcation is largely based
on the extent of systemic leukemia, hypercalcemia, and organ
involvement. The chronic and smoldering subtypes are considered
indolent, but eventually have poor long-term survival. The acute
and lymphoma forms generally have a worse prognosis mainly
due to their resistance to the conventional chemotherapies, a
large tumor burden, hypercalcemia, and/or frequent infectious
complications as a result of a profound T-cell immunodeﬁciency
(Shimoyama,1991;Hermine et al., 1998; Bazarbachi andHermine,
2001; Bazarbachi et al., 2004).
HTLV-1 is transmitted by three routes: (1) vertical (mother-
to-child through breast-feeding), (2) horizontal (sexual), and (3)
parenteral (blood transfusion or intravenous drug abuse) routes.
Via any of the routes, infected cells are essential for transmission
of HTLV-1, which has been demonstrated by the absence of sero-
converters among recipients of fresh frozen plasma transfusions
(Okochi et al., 1984).
A genetically related virus, HTLV-2, has been identiﬁed and
isolated (Kalyanaraman et al., 1982). However, there has been
no demonstration of a deﬁnitive etiological role for HTLV-2
in a human disease to date. HTLV-2 was originally identiﬁed
from a patient with a variant form of hairy T-cell leukemia
(Kalyanaraman et al., 1982) and is so far loosely correlated with
TSP/HAM (Murphy et al., 1997a) or other opportunistic infec-
tions attributable to immunocompromised patients (Murphy
et al., 1997b).
In 2005, the discovery of HTLV-3, a third HTLV type, was
reported in two Cameroonese asymptomatic individuals living in
the rainforest area of the southern part of the country (Calattini
et al., 2005; Wolfe et al., 2005; Mahieux and Gessain, 2011). The
fourthHTLV type (HTLV-4)was also reported in 2005 and consists
only, so far, of a unique human strain, whose provirus was also
found in the blood of a hunter living in Cameroon (Calattini et al.,
2005). However, association of HTLV-3 and -4 with any human
disease remains unconﬁrmed due to the limited number of cases
in which these viruses have been identiﬁed (Thomas et al., 2010;
Zheng, 2010; Mahieux and Gessain, 2011; Welsh, 2011).
EXPERIMENTAL ANIMAL MODELS
ANIMAL MODELS FOR BLV
Sheep are excellent models to study and follow BLV infection
Large animals often provide a more relevant model of human
cancer as compared to mice, since disease chronology and relevant
physiology are more accurately replicated. BLV transmission has
been reported in rabbits (Wyatt et al., 1989; Onuma et al., 1990),
rats (Altanerova et al., 1989; Boris-Lawrie et al., 1997), chicken
(Altanerova et al., 1990), pigs (Mammerickx et al., 1981), and goats
(Olson et al., 1981). However, the most consistent model to study
BLV infection is the sheep (Djilali et al., 1987; Djilali and Parodi,
1989; Zhao et al., 2005).
AlthoughBLV-associated ovine leukemia is a B-cellmalignancy,
it shares many similarities withATL and has been extensively stud-
ied as a model for unraveling leukemogenic mechanisms (Willems
et al., 2000; Gillet et al., 2007; Merimi et al., 2009). Since the com-
plete onset of the disease occurs in a relatively short period of
time (18 months average), this model was used for studying anti-
leukemic immune responses prior to tumor onset. In addition, this
model has been extensively used to develop potential treatment or
vaccine against BLV infection in cattle as well as to correlate these
approaches with HTLV-1-associated ATL.
As for the other complex retroviruses, in addition to the Gag,
Pol, and Env structural and enzymatic proteins, the genome of
BLV encodes essential regulatory and accessory proteins such as
Tax and Rex (Figure 1B).
Malignant progression following BLV infection in sheep is
dependent on the viral Taxoncoprotein (Yoshida et al.,1982; Burny
et al., 1987; Willems et al., 1990; Schwartz and Levy, 1994; Mar-
riott et al., 2002; Szynal et al., 2003; Jeang et al., 2004; Yoshida,
2005; Klener et al., 2006; Matsuoka and Jeang, 2007). Van den
Broeke et al. (2010) developed a retrovirus transduction sys-
tem to generate autologous B-cell lines expressing Tax. This
group demonstrated that the induction of a Tax-speciﬁc cyto-
toxic response by DNA immunization or viral infection of naïve
animals was not predictive of disease outcome and did not pre-
vent tumor development. On the other hand, Florins et al. (2009)
demonstrated that the integrity of the spleen is required to con-
trol pathogenesis because asplenia decreased the efﬁciency of the
immune response and induced an imbalance in cell dynamics
resulting in accelerated onset of leukemia.
Bovine leukemia virus-infected sheep were also used to pro-
vide insights on the molecular genetic and epigenetic modulation
of viral expression. On the genetic level, infectious proviruses were
cloned and injected into sheep or calves to study the viral genetic
determinants required for infection and pathogenesis (Rovnak
et al., 1993; Adam et al., 1994; Bartoe et al., 2000; Tana et al., 2001).
One proviral clone (clone 344) leads to tumor or leukemia after
a mean latency period of 33 months (Lefèbvre et al., 2002). This
clone has been used to construct a series of derivative proviruses
harboring mutations or deletions in different parts of the genome
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including gag, pol, or env genes whose deletions destroy infectiv-
ity in vivo (Onuma et al., 1987; Adam et al., 1994). The deletion
of the region which expands from the end of the env gene to the
splice acceptor site of the tax/rex mRNAdoes not impair infectivity
(Adam et al., 1994). Since these sequences correspond respectively
to the third and second exons of the R3 and G4 mRNAs, it appears
that these genes are not essential for infectivity in vivo. When
p12I and p13II/p30II orthologs of R3 and G4 were deleted, sim-
ilar results were obtained (Collins et al., 1998; Van den Broeke
et al., 2001; Silverman et al., 2004). Importantly, the R3/G4 dele-
tion greatly interferes with the efﬁciency of BLV propagation and
restricts pathogenesis (Powers et al., 1991; Lefèbvre et al., 2002).
However, one out of 20 sheep infected with a R3/G4 mutant devel-
oped a lymphoma after 7.5 years of latency, demonstrating that
the deleted sequences are not strictly required for pathogenesis
(Florins et al., 2007). Among other isolates, clone 395 is deﬁ-
cient for infectivity in vivo, due to the presence of a mutation
at codon 303 of the Tax protein (Adam et al., 1994; Tajima et al.,
1998; Twizere et al., 2003). This result illustrates that Tax transacti-
vation activity is required for viral infectivity in vivo. In contrast, a
provirus (Tax106+293) harboring mutated phosphorylation sites
remains infectious and propagates at wild-type levels in sheep. In
addition, the Tax106+293 mutant is pathogenic despite a loss in
its ability to transform primary cells in vitro (Szynal et al., 2003).
The BLV transcriptional promoter located in the 5′ LTR contains
suboptimal binding sequences for the CREB transcription fac-
tor. Remarkably, the cyclic-AMP responsive site (CRE) consensus
“TGACGTCA” is never strictly conserved. When a perfect CRE
sequence is restored, the promoter’s activity increases. However,
the proviral loads are drastically reduced in sheep infected with a
virus harboring this type of change (Calomme et al., 2004).
On the epigenetics level, a subtle equilibriumbetween the virus,
which attempts to replicate, and the immune response,which seeks
to exert tight control of the pathogen appeared to be tightly reg-
ulated by histone acetylation and DNA hypermethylation. In BLV
infected cells, the virus is stably integrated apparently in a tran-
scriptionally silent state (Kettmann et al., 1980; Gupta and Ferrer,
1982; Kashmiri et al., 1985; Van den Broeke et al., 1988; Lagarias
andRadke, 1989; Kerkhofs et al., 1996; Merimi et al., 2007a,b). Two
epigenetic mechanisms, histone acetylation and DNA hyperme-
thylation, correlate with BLV transcriptional repression (Merezak
et al., 2002; Tajima et al., 2003; Calomme et al., 2004; Nguyên et al.,
2004; Achachi et al., 2005; Pierard et al., 2010). A key observation
in the BLV sheep model was a paradoxical decrease in proviral
loads when increasing the BLV promoter efﬁciency (Merezak et al.,
2001). This process was highly modulated by epigenetic modiﬁ-
cations on the promoter sequence. In this context, a therapeutic
approach based on the modulation of host epigenetic mechanisms
was proposed to treat BLV infection and disease (Grange et al.,
2000; Novakovic et al., 2004; Achachi et al., 2005). Different his-
tone deacetylase (HDAC) inhibitors including valproate (VPA),
trichostatin A (TSA), and trapoxin (TPX) efﬁciently enhanced
viral transcription directed by the BLV promoter in vitro (Merezak
et al., 2002; Achachi et al., 2005). HDAC inhibitors also increased
viral expression during ex vivo short-term culture of PBMCs from
BLV-infected sheep and cattle (Merezak et al., 2002; Achachi et al.,
2005). VPA-induced hyperacetylation of histone H3 (Bouzar et al.,
2009) and in the absence of any other cytotoxic drug,VPA-induced
tumor regression inBLV-infected sheep. However, this therapywas
inefﬁcient for preventing primary infection or reducing proviral
load in asymptomatic sheep (Achachi et al., 2005).
The BLV-infected sheep model was also used to unravel the
relative importance of cell proliferation versus apoptosis during
the process of leukemogenesis associated with infection by com-
plex oncoviruses. Debacq et al. (2002) measured the rates of cell
proliferation and death in the BLV-ovine system, by using the
i.v. injection of 5-bromodeoxyuridine into BLV-infected sheep.
Their results showed that the increase in the number of B cells
during BLV-induced lymphocytosis results from an increased cell
proliferation rather than a reduced cell death.
Rats and rabbits provide a tool for BLV vaccination
Ideally, the optimal vaccine shall contain a large number of viral
factors permanently stimulating the immune response. Attenuated
derivatives of BLV proviruses meet these requirements (Willems
et al., 1993, 1997, 2000; Boris-Lawrie et al., 1997; Kucerova et al.,
1999; Kerkhofs et al., 2000; Altanerova et al., 2004; Debacq
et al., 2004; Florins et al., 2007). Replication-competent BLV
proviruses lacking accessory genes and cis-acting LTR sequences
were designed and evaluated in rats and rabbits. A ﬁrst generation
of these genetically simpler viruseswas constructed by co-injection
of independent vectors encoding gag-pol and env genes. These
constructs were devoid of tax, rex, R3, and G4 and contained
promoter cis-acting regulatory sequences of spleen necrosis virus
(SNV). These BLV simpler hybrid derivatives were infectious and
induced speciﬁc antibodies in a rat model (Boris-Lawrie et al.,
1997). A second type of virus contained gag, pol, and env genes in
a single genome under the control of SNV regulatory sequences.
This viral vector was competent for replication and induced anti-
body responses against gag and env structural proteins in rats and
rabbits (Boris-Lawrie et al., 1997; Kucerova et al., 1999; Altane-
rova et al., 2004). This viral vector induced protection against
viral challenge in a rabbit model and decreased the proviral load
(Altanerova et al., 2004).
ANIMAL MODELS FOR PTLV
Non-human primates are both natural hosts and
experimental models for STLV infections
Various species of NHP serve as the natural hosts for at least
six exogenous retroviruses, including gibbon ape leukemia virus
(GaLV), simian sarcoma virus, simian immunodeﬁciency virus
(SIV), STLV, simian type D retrovirus (SRV), and simian foamy
virus (SFV; Lowenstine and Lerche, 1988). Asian monkeys of
the genus Macaca, are natural hosts for three of these viruses
(SRV, SFV, STLV; Lowenstine et al., 1986; Daniel et al., 1988).
These Macaques were widely used in diverse studies including
vaccination and toxicology against retroviruses.
Using the primate animal model, Dezzutti et al. (1987) chal-
lenged vaccinated pig-tailed macaques with the HTLV-1 sub-
unit vaccine by an STLV-1-infected cell line. An antibody
response developed to HTLV-1 and STLV-1 viral proteins rec-
ognizing both gag and env proteins. Importantly, mononuclear
cells from immunized monkeys produced a greater cytotoxic
activity demonstrating that the HTLV-1 subunit vaccine was
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successful in protecting the pig-tailed macaques from the STLV-1
infection.
The primate animal model was also used in order to investigate
the mode of transmission of HTLV-1 by studying the transmission
of its related STLV-1. This study consisted of breeding seronegative
macaques females with seropositive males and showed that sexual
contact is important in the transmission of STLV-1, but it may not
be an efﬁcient mode of viral infection (Lazo et al., 1994).
On the molecular level, since the expression of the HTLV-1
provirus is epigenetically regulated, and since the low level of viral
expression is associatedwith proviral chromatin deacetylation and
condensation (Ego et al., 2002; Lu et al., 2004), an STLV-1 model
was of great importance to study thesemechanisms in vivo. Indeed,
approximately 3% of all HTLV-1 infected persons will develop
TSP/HAM against which there is currently no efﬁcient treatment.
Differences between the immune systems of rodents and humans
cannot be ignored, particularly in models of TSP/HAM, because
immune-mediated mechanisms appear to contribute to its devel-
opment (Moore et al., 1989; Levin et al., 1997). As a correlation
exists between the proviral loads (PVL) and the clinical status of
the carrier, it is thought that diminishing the PVL could prevent
later occurrence of the disease. In order to decrease the PVL, the
STLV-1 model consisted of baboons (Papio papio) that are natu-
rally infected with this virus. Baboons constitute an interesting,
but little-used, model of asymptomatic HTLV-1 infection (Wolfe
et al., 2005). Indeed, their immune system is very similar to the
humans and the animals are naturally infected with STLV-1, and
some develop STLV-1-associated diseases, such asATL (Allan et al.,
2001). Afonso et al. (2010) conducted a study combining VPA
and zidovudine (AZT) in a series of baboons. They showed that
the VPA/AZT combination induced a strong decrease in the PVL,
which correlated with an increase in the STLV-1-speciﬁc cytotoxic
T-cell population.
Non-human primates were also used to test the hypothesis
that coinfection with human immunodeﬁciency virus (HIV) and
HTLV-1 or -2 accelerates progression to AIDS. Fultz et al. (1999)
inoculated pig-tailed macaques with the simian counterparts, SIV
and STLV.During 2 years of follow-up of singly and dually infected
macaques, no differences in SIV burdens, onset of disease, or sur-
vival were detected. However, in the ﬁrst coinfected macaque that
died of AIDS (1 year after infection), >50% of CD4+ and CD8+
lymphocytes expressed CD25. On the basis of the low incidence
of HTLV-1- and STLV-1-associated disease during natural infec-
tions, this early evidence of neoplastic disease was unexpected.
In the same direction, Gordon et al. (2010) generated a coinfec-
tion animal model to investigate the effect of HTLV-2 on T-cell
response and its impact on SIV. They found that inoculation of
irradiated HTLV-2 cells in macaques elicited humoral and T-cell
responses toHTLV-2 at both systemic andmucosal sites. Their data
provided insights on the potential development of an attenuated
HTLV-2-based vector vaccine for HIV-1.
Rabbits are excellent models to study the immunological
response against HTLV-1
Haynes et al. (2010a) established a rabbit HTLV-1 infection model
to study early spatial and temporal events of the viral infec-
tion. Twelve-week-old rabbits were injected intravenously with
cell-associatedHTLV-1. Blood and tissueswere collected at deﬁned
intervals throughout the study to test the early spread of the
infection. Antibody and hematologic responses were monitored
throughout the infection. This group showed that intravenous
infection with cell-associated HTLV-1 targets lymphocytes located
in both primary lymphoid and gut-associated lymphoid com-
partments. A transient lymphocytosis that correlated with peak
virus detection parameters was observed by 1 week postinfec-
tion, before returning to baseline levels, suggesting that HTLV-1
promotes lymphocyte proliferation preceding early viral spread
in lymphoid compartments to establish and maintain persistent
infection (Haynes et al., 2010a). Moreover, Haines et al. developed
an oral model of HTLV-1 transmission in rabbits to allow test-
ing of the mucosal microenvironment during the early stages of
orally acquired HTLV-1 (Martin et al., 2011). Valeri et al. (2010)
suggested that infection of dendritic cellsmight be required for the
establishment and maintenance of HTLV-1 infection in primate
species. This conclusion was reached after their interesting ﬁnd-
ing established after the ablation of p12, p30, and HBZ proteins.
In fact, none of these proteins, when ablated, could affect viral
infectivity in rabbits. Interestingly, in rabbits, only the absence
of HBZ is associated with a consistent reduction in virus lev-
els. In contrast, in macaques, the absence of HBZ or p30 was
associated with reversion of the mutant virus to the wild-type
genotype. The macaques exposed to the p12 knockout remained
seronegative. Interestingly, p12 and p30 mutants were severely
impaired in their ability to replicate in human dendritic cells
(Valeri et al., 2010). Furthermore, since HTLV-1-infected patients
treatedwith immunosuppressive drugs, typically for organor bone
marrow transplantation procedures, often exhibit an accelerated
or altered course for the development of HTLV-1-associated dis-
eases (Gout et al., 1990; Brezin et al., 1995; Tsukasaki et al., 1999;
Tajima and Aida, 2000), the rabbit model was used to evaluate
the effects of immune suppression on the early spread of HTLV-
1 infection upon treatment with cyclosporine A. Haynes et al.
(2010b) concluded that immunologic control during early virus
exposure determines subsequent HTLV-1 spread and has impor-
tant implications for therapeutic intervention strategies and the
development of HTLV-1-associated diseases.
Rats provided new insights on the relationship of
regulatory T cells and ATL
The relationship of ATL cells with regulatory T cells (Treg) was
intensively studied in order to explain the reasons behind the
immunodeﬁciency in ATL patients. Some ATL cells and HTLV-
1-infected human cells express Foxp3 and related molecules,
such as CTLA-4 and GITR (Karube et al., 2004; Kohno et al.,
2005; Matsubara et al., 2005; Roncador et al., 2005). To ana-
lyze the contribution of Foxp3 and Treg associated molecules
to the development of ATL in more detail, various rat models
for HTLV-1 infection including inbred and immunocompromised
rats were generated (Ohashi et al., 1999; Nomura et al., 2004). Shi-
nagawa et al. constructed a transgenic rat expressinghumanCRM1
(hCRM1), a cellular cofactor of Rex, and demonstrated that T cells
derived from transgenic rats allowed production of HTLV-1 as
efﬁciently as human T cells (Hakata et al., 2001; Takayanagi et al.,
2007; Martin et al., 2011). Their results suggest the presence of
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inhibitor(s) during the entry process in rat dendritic cells (Martin
et al., 2011).
Mouse models: a breakthrough in HTLV studies
Small animal models are the most efﬁcient method of study-
ing human afﬂictions. This is particularly evident in the study
of the human retroviruses, especially HTLV-1. Indeed, although
simian models were very useful to elucidate the mechanisms of
early infection and cell-to-cell transmission and to study antivi-
ral immunological responses and potential vaccine development,
they remain expensive and difﬁcult to maintain. Mice provide
a cost-effective and highly reproducible model to study factors
related toATLdevelopment and the preclinical efﬁcacy of potential
therapies. Transgenic mice have provided important insight into
viral genes responsible for lymphocyte transformation. Expan-
sion of various strains of immunodeﬁcient mice has accelerated
the testing of drugs and targeted therapy against ATL.
XENOGRAFT MICE MODELS
DEVELOPMENT OF IMMUNOCOMPROMIZED MICE STRAINS
Over the past two decades, the construction of humanized animal
models through the transplantation and engraftment of human
tissues or progenitor cells into immunocompromised mouse
strains has allowed the development of a reconstituted human tis-
sue scaffold in a small animal system. The ﬁrst humanized mouse
model was developed in 1983 through the discovery of the scid
mutation in CB-17 scid/scid (SCID) mice (Bosma et al., 1983).
This mouse contains a spontaneous non-sense mutation in the
gene for the protein kinase DNA activated catalytic polypeptide
(Pkrdc). The Pkrdc enzyme is necessary for the efﬁcient recom-
bination of the B- and T-cell receptors. Without this enzyme,
mature B and T cells do not develop. The SCID mouse retains nor-
mal macrophage, antigen-presenting cell, and natural killer (NK)
cell functions (Bosma et al., 1983). SCID mice are used exten-
sively in human stem cell and tumor cell engraftment studies.
This mouse model resulted in animals demonstrating improved
engraftment efﬁciency and infectivity. The SCID/beige mouse
(CB17.B6-Prkdcscid/Lystbg) is a double mutant mouse in which
the SCID mutation is retained, but these mice have an additional
beige mutation in the Lyst gene that results in altered lysosomal
trafﬁcking. These mice have defective B- and T-cell function, NK
cell activity, and granulocyte properties.
Engraftment efﬁciency was further improved through the inte-
gration of the non-obese diabetic (NOD) mutation leading to
the creation of NOD/SCID, a good model used to study the
development of autoimmune-mediated insulin-dependent dia-
betes mellitus. The resultant NOD/SCID mice lack functional B
and T cells, have low NK cell activity, lack complement activity,
and have impaired macrophage and antigen-presenting cell func-
tion. Other immunodeﬁcient models were also created including
NOD/SCID β2-microglobulinnull animals. These later were pro-
duced with development of the NOD/SCID mouse containing
a targeted mutation in the β-2 microglobulin gene, encoding a
protein necessary for the presentation of antigens via major his-
tocompatibility class I. These mice lack all the immune functions
that their less immunodeﬁcient NOD/SCID predecessors also lack
but have more complete elimination of NK-cell function.
Further efforts at minimizing the immune response resulted
in the generation of NOG (NOD/Shi-scid IL2rγ−/−) mice. These
mice are homozygous for the SCID mutation and a targeted dis-
ruption of the IL-2Rγ gene mutation. The γ chain is common to
the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. NOGmice
are easily transplanted with human cells that would not normally
transplant with the same efﬁciency in the more immunocompe-
tent mouse models. NOG mice lack B- and T-cell development
as well as NK-cell function and have a severe reduction in inter-
feron (IFN)-γ production from dendritic cells. In order to further
reduce the innate murine immune system, the Rag2−/−γc−/−
model was generated and constituted an important advancement
for the engraftment of human CD34+ hematopoietic stem cells.
These mutant mice were created by crossing homozygous recom-
binase activating gene 2 (Rag2) knockout mice with homozygous
common cytokine receptor γ chain (γc) knockouts. The Rag2
mutation results in the lack of maturation of thymus derived T
cells and peripheral B cells whereas the γc mutation results in
the lack of the functional subunit of the IL-2, IL-4, IL-7, IL-9,
and IL-15 receptors, preventing the development of lymphocytes
and NK cells. The Rag2 knockout is not a leaky mutation: it does
not result in spontaneously forming tumors, and does not con-
fer radiation-sensitivity to the mice as the SCID mutation does.
Therefore, the Rag2−/−γc−/− mouse may be an ideal scaffold
for repopulation of the animal with human hematopoietic cells
(Greiner et al., 1995; Hesselton et al., 1995; Christianson et al.,
1997; Ito et al., 2002; Ishikawa et al., 2005; Shultz et al., 2005; Ito
et al., 2008; Pearson et al., 2008). Together, these animal mod-
els have revolutionized the investigation of retroviral infections
in vivo.
XENOGRAFTS OF HTLV-1 TRANSFORMED OR ATL CELLS IN
IMMUNE-COMPROMIZED MICE
Xenografts of ATL cells or cell lines into immunodeﬁcient mice
replicate features of ATL and provide systems to test therapies
(Zimmerman et al., 2010). Early attempts to establish an HTLV-
1 infection in vivo involved inoculation of the CB17-scid mice
with peripheral blood lymphocytes or PBMCs from HTLV-1
healthy carriers. These experiments were promising although
limited in success due to engraftment inefﬁciencies and poor
detection of viral integration (Feuer et al., 1993; Kondo et al.,
1993). Feuer et al. (1996) used the SCID mouse model to compare
the engraftment achieved with either HTLV-1-infected human
hematopoietic progenitor CD34+ cells or in vitro HTLV-1 trans-
formed cell lines SLB-1 and MT-2. This group showed that not
only human hematopoietic progenitor cells could be infected via
co-culture with cell lines transformed with HTLV-1 and HTLV-2,
but that upon inoculation into immunocompromised mice, infec-
tion could be detected in biopsies from the thymus or the liver.
When the same model was challenged using only the transformed
cell lines SLB-1 and MT-2, infection could be also be detected
in biopsies from the same organs, although levels were not as
impressive as those achieved with the hematopoietic progenitor
cells. These results pointed to a role for hematopoietic cells in
HTLV-1 infection (Feuer et al., 1996).
To improve the efﬁcacy of engraftment, Liu et al. (2002) used
different HTLV-1 infected cell lines (RV-ATL cells) derived from a
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patient sample. This groupnoted that a higher level of engraftment
could be achieved through the use of an HTLV-1 transformed
cell line as opposed to cell lines that were immortalized through
transfection, which did not produce lymphomas in NOD/SCID
animals. These cells were reported to establish tumors readily, but
must be propagated through mice because they did not remain
viable in cell culture (Liu et al., 2002). This RV-ATL cell line
was reported to engraft in approximately 75% of the SCID/beige
mice, whereas transformed cells (HT-1-RV, SLB-1, MT-2, ACH,
and ACH.p12) were unable to establish engraftment (Liu et al.,
2002). These results illustrate the signiﬁcant difference between
ATL cell lines derived from patients versus those transformed ex
vivo by HTLV-1. Furthermore, using C3H/HEJ model inoculated
with MT-2 cells, Tanaka et al. (2001) demonstrated integration
of the virus and concentration of infected cells in lymphoid
tissue.
Kawano et al. (2005) developed a novel xenogeneic engraftment
model in which primary ATL cells are transplanted intravenously
into neonatal NOG SCID mice. Engrafted ATL cells were dually
positive for human CD4 and CD25, and displayed patterns of
HTLV-1 integration identical to those of donors. Engrafted mice
showed monoclonal or polyclonal proliferation of ATL cells in
blood and lymph nodes, evidenced by clinical features speciﬁc to
each subtype of transplanted ATL.
TARGETING THE NF-κB PATHWAY IN XENOGRAFT MODELS
Nuclear factor-κB (NF-κB) is a transcription factor constitu-
tively activated in HTLV-1 infected and ATL cells (reviewed in
Kfoury et al., 2005). NF-κB regulates the expression of a wide
variety of genes implicated in proliferation, angiogenesis, invasion,
and metastasis. Importantly, HTLV-1-induced transformation is
dependent on the NF-κB activation, which makes this pathway an
ideal target for therapeutic attack.
In tissue culture and mouse models, non-speciﬁc inhibitors
of the NF-κB pathway such as sodium salicylate or cyclopen-
tenone prostaglandins can increase the sensitivity of Tax-tumor
cells to apoptosis and repress NF-κB-inducible cytokines IL-6, IL-
10, IL-15, and IFN-γ (Portis et al., 2001). The proteasome inhibitor
bortezomib is another non-speciﬁc inhibitor of the NF-κB path-
way that is capable of inhibiting proliferation of ATL cells ex vivo
and sensitizing them to apoptosis (Nasr et al., 2004; Mitra-Kaushik
et al., 2004). Bortezomib inhibits the degradation of the NF-κB
inhibitor IκBα, resulting in reversal of NF-κB activation. Hence,
bortezomib treatment slowed tumor growth in an allograft model
of ATL by increasing apoptosis, but toxicity constraints limited its
efﬁcacy (Mitra-Kaushik et al., 2004). Similarly, when bortezomib
was administered into SCID mice bearing tumors, it suppressed
tumor growth in vivo; conﬁrming that bortezomib was effective
against ATL cells in vivo (Satou et al., 2004).
Another inhibitor of NF-κB DNA binding activity, BAY 11-
7082, was also shown to induce tumor regression in ATL trans-
planted NOG mice (Dewan et al., 2003). Similarly, Ohsugi et al.
(2006, 2007) explored the use of the NF-κB inhibitor dehy-
droxymethylepoxyquinomicin (DHMEQ) as a therapeutic agent.
They established a model for infection in the NOD/SCID β2-
microglobulin null mice by sublethally irradiating 7–10-week-old
animals and injecting them with transformed HTLV-1 cell lines
the following day. Treatment with DHMEQ showed increased
survival and growth inhibition of ATL cells in animals that had
been infected through inoculation with HTLV-1 producing cell
lines.
Finally, under a similar aim in targeting and understanding the
NF-κB involvement in vivo, Nitta et al. (2008) utilized a mouse
model with a defect in NF-κB inducing kinase (NIK) gene result-
ing in a phenotype of alymphoplasia (aly/aly). These investigators
used this model to evaluate the importance of NIK for the estab-
lishment of HTLV-1 infection and associated pathology. Aly/aly
mice were compared with C57BL/6J and BALB/c mice. All ani-
mals were inoculated intra-peritoneally with MT-2 cells, and PCR
was used to evaluate PVL. Aly/aly animals demonstrated dramat-
ically lower PVLs, suggesting that NIK plays an essential role in
HTLV-1 infection and could serve as a potential target for ther-
apeutic intervention (Nitta et al., 2008). Altogether, these results
conﬁrm the importance of NF-κB activation in ATL development
and demonstrate that NF-κB inhibition can slow ATL growth, but
is not sufﬁcient for ATL eradication.
TESTING MONOCLONAL ANTIBODIES IN XENOGRAFT
MICE MODELS
The expression of markers on the cell surface of ATL cells
implanted in mice has made them an excellent target for pre-
clinical trials with monoclonal antibodies. Monoclonal antibodies
directed against IL-2Rα (Phillips et al., 2000), CD25, CD52, and
CD2 (Zhang et al., 2003a,b, 2005) were tested. Phillips et al.
(2000) established a NOD/SCID animal model by introducing
cells from an ATL patient (MET-1), which are activated T cells
that express CD2, CD3, CD4, CD25, CD122, and CD52, into
the mice. The disease progressed to death in this animal model
after approximately 4–6 weeks. When they treated the animals
with humanized anti-Tac (HAT), murine anti-Tac (MAT), and
7G7/B6, all of which are directed to CD25 (IL-2Rα), they noticed
that all of the treatments signiﬁcantly delayed the progression of
the leukemia and prolonged the survival of the tumor-bearing
mice. Moreover, and using the same animal model, Zhang
et al. (2005) investigated the therapeutic efﬁcacy of ﬂavopiridol,
an inhibitor of cyclin-dependent kinases, alone and in combi-
nation with HAT. They obtained a prolonged survival and a
dramatically enhanced antitumor effect, with the combination
therapy. Zhang et al. (2005) evaluated the efﬁcacy of Campath-
1H (alemtuzumab; a humanized monoclonal antibody directed
to CD52), alone and in combination with HAT or with MEDI-
507 directed to CD2. They noticed that the survival of the group
receiving the Campath-1H was signiﬁcantly longer than that of
the group receiving the HAT. Furthermore, the main tumor
killing mechanism with Campath-1H in vivo involves FcRgamma-
containing receptors (e.g., FcRgammaIII) on polymorphonuclear
leukocytes and macrophages that mediate antibody-dependent
cellular cytotoxicity and/or trigger cross-linking induced apopto-
sis (Zhang et al., 2003a,b). The outcome of these mouse studies
may be predictive of successful therapy for human patients,
because a complete response has been reported in an ATL patient
treated with alemtuzumab (anti-CD52; Mone et al., 2005). Maeda
et al. (2010) investigated the effect of CD30-mediated therapy
on ATL by using SGN-30, a chimeric anti-CD30 mAb, and
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SGN-35, a monomethyl auristatin E-conjugated anti-CD30 mAb,
in vitro and in vivo. They used NOD/SCID mice subcutaneously
engrafted with HTLV-1-infected cell lines. Both mAbs signiﬁ-
cantly inhibited the growth of HTLV-1-infected cell tumors in
NOD/SCID xenograft models, suggesting that CD30-mediated
therapy with SGN-30 or SGN-35 would be useful for patients
with ATL.
HUMANIZED MICE MODELS
Miyazato et al. (2006) took the next step in 2006 when they
designed an experiment utilizing the NOG mouse model. Their
investigation involved inoculation with human PBMCs in order
to establish a humanized system, followed by inoculation with
the MT-2 cell line to allow for the required cell-to-cell transmis-
sion essential for HTLV-1 infection. Important ﬁndings included
the detection of an increased PVL in both CD4+ and CD8+
T cells. Additionally, they were able to demonstrate that pro-
phylaxis with the reverse transcriptase inhibitors tenofovir and
azidothymidine (AZT) was successful in preventing new HTLV-
1 infection in these animals. Takajo et al. (2007) were able to
achieve similar results in 2007 when they also established HTLV-
1 infection in NOG mice through the inoculation of PBMCs
from HTLV-1-infected individuals. Although the approach was
different, they conﬁrmed that these animals could harbor HTLV-1
infection and they demonstrated the presence of detectable viral
integration.
Another attempt to explore treatment options included a novel
approach to detect tumor growth. Shu et al. (2007) established
a bioluminescent mouse model in the older CB17-scid model
by infecting the animals with the ATL cell line, RV-ATL, and a
lentivirus harboring the luciferase gene. These investigators were
able to non-invasively measure the tumor growth and expansion
that occurred in the recipient mice. Additionally, they tested a
bisphosphonate, zoledronic acid, and the proteasome inhibitor
bortezomib. Both compounds demonstrated some level of suc-
cess in reducing the development of tumors, as well as levels of
parathyroid hormone related protein (PTHrP) and macrophage
inﬂammatory protein-1α (MIP-1α) which are both indicators of
malignant hypercalcemia, a complicationobserved in 60%of acute
ATL patients (Shu et al., 2007).
Chen et al. (2009) utilized the NOD/SCID mouse inoculated
with an ATL cell line, MET-1, in their investigation of the use
of a HDAC inhibitor, depsipeptide, along with daclizumab as a
therapeutic option in the murine HTLV-1 infection model. They
demonstrated that both depsipeptide and daclizumab alone and
when used in combination were able to increase the survival of the
animals.
ROLE OF HEMATOPOIETIC STEM CELLS IN HTLV-1
HUMANIZED MICE MODELS
In order to identify the molecular and cellular events that control
the initiation and progression of ATL and potential therapeu-
tic targets to block tumor development, Banerjee et al. (2010)
generated an HTLV-1-infected humanized (HU-NOD/SCID)
mouse model. This model was obtained by inoculation of
NOD/SCID mice with CD34+ hematopoietic progenitor and
stem cells (CD34+ HP/HSCs) infected ex vivo with HTLV-1.
HTLV-1-HU-NOD/SCID mice exclusively developed CD4+ T-
cell lymphomas with characteristics similar to ATL. Impor-
tantly, an increased proliferation of infected human stem cells
(CD34+CD38−) in the bone marrow was observed in mice devel-
oping malignancies. Furthermore, CD34+ HP/HSCs puriﬁed
from the PBMCs of an HTLV-1-infected patient revealed proviral
integrations suggesting viral infection of human bone marrow-
derived stem cells. NOD/SCID mice reconstituted with CD34+
HP/HSCs transduced with a lentivirus vector expressing the
HTLV-1 oncoprotein Tax also developed CD4+ lymphomas. The
recapitulation of a CD4+ T-cell lymphoma in HU-NOD/SCID
mice suggests that HSCs provide a viral reservoir in vivo and act
as cellular targets for cell transformation in humans.
Tezuka et al. reported the development of ATL-like disease
in humanized mice (huNOG) by the intra-bone marrow trans-
plantation of NOG-SCID mouse with CD133+ hematopoietic
stem cells puriﬁed from human cord blood infected with HTLV-1
(Martin et al., 2011). Inverse PCR analysis of provirus integra-
tion sites revealed oligoclonal expansion of infected T cells in
CD4+/CD25+ T cells similar to HTLV-1-infected humans. Vil-
laudy et al. (2011) reported that HTLV-1 induces alterations of
the thymus of Rag2−/IL-2R γc− mice leading to expanded pop-
ulations of mature CD4+/CD25+ T cells and other pathological
features such as splenomegaly and lymphomas as compared to
mock-infected mice. This unique model system was then used to
test anti-cancer drugs, further illustrating the usefulness of the
model (Martin et al., 2011; Villaudy et al., 2011).
ROLE OF THE IMMUNE SYSTEM IN HTLV-1 INFECTION
AND ATL DEVELOPMENT
In order to understand the immune response against HTLV-1
in infected patients, xenografted mouse models were of great
importance. Stewart et al. (1996) demonstrated that SCID mice
NK cells mediated speciﬁc lysis of HTLV-1-expressing cell lines,
suggesting that the absence of HTLV-1 expression in patient-
derived ATL lines allows these cells to evade immune surveillance.
Whole-body irradiation or administration of antibodies to abro-
gate NK-cell function proved necessary to establish engraftment
of non-leukemic cell lines such as SLB-1 cells (Feuer et al., 1995;
Uchiyama, 1996; Liu et al., 2002). MT-2 cells developed tumors at
the site of injection in SCID mice treated with anti-asialo GM-1
antibody, which functionally inactivates NK cells (Ishihara et al.,
1992). Indeed, invariantNKT cells (iNKT) are inversely correlated
to PVLs in ATL patients (Azakami et al., 2009).
TRANSGENIC MICE MODELS OF HTLV-1
Transgenic animal technology has been useful for the direct
demonstration of the tumorigenic potential of oncogenes in vivo.
Over the recent years, a wide variety of oncogenes and proto-
oncogenes from viral and cellular sources have been inserted into
the germline of mice with subsequent development of neoplasia.
These models continue to provide new insights into the molec-
ular mechanisms of HTLV-1-associated transformation. None of
the transgenic mice models fully recapitulate HTLV-1-associated
disease, but many have been useful to investigate Tax-mediated
disruption of lymphocyte function or provide evidence that Tax is
an oncoprotein.
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THE HTLV-1 ONCOPROTEIN Tax
In addition to its effects on the transactivation of the viral LTR,
Tax has pleiotropic cellular functions (Franchini, 1995; Gatza et al.,
2003; Matsuoka, 2003). It stimulates the transcription of several
cellular genes through activation of critical transcription factors
such as NF-κB (Sun et al., 1994; Good and Sun, 1996; Uhlik et al.,
1998; Xiao et al., 2001); cyclicAMP response element-binding pro-
tein (CREB; Zhao and Giam, 1992; Suzuki et al., 1993), serum
responsive factor (SRF; Fujii et al., 1992), and activated protein 1
(AP-1; Fujii et al., 2000). Tax also represses the expression of cel-
lular genes such as DNA polymerase β (Jeang et al., 1990), cyclin
A (Kibler and Jeang, 2001), and transforming growth factor β
(Arnulf et al., 2002). Moreover, Tax is involved in the regulation of
apoptosis through the activation of apoptosis-suppressing genes
such as Bcl-XL (Nicot et al., 2000) and repression of apoptosis-
inducing genes such as Bax (Brauweiler et al., 1997). Tax inhibits
tumor suppressor proteins such as p53 and p16, interferes with
cell cycle checkpoint control and enhances the accumulation of
mutations in HTLV-1-infected cells through the repression of
DNA repair (Suzuki and Yoshida, 1997; Pise-Masison et al., 1998).
Tax also inﬂuences the microenvironment: it induces angiogene-
sis and gap junction mediated communication between infected
cells and endothelial cells, hence contributing to the extravasation
and invasiveness of ATL cells (El-Sabban et al., 2002; Bazarbachi
et al., 2004). Recent observations suggested that Tax also modu-
lates the micro-RNA environment thereby adding another level of
complexity to its cellular functions (Jeang, 2010). Indeed, a recent
study (Yamagishi et al., 2012) has shown thatMi-RNA31negatively
down-regulates the non-canonical NF-κB pathway by targeting
NIK. Aberrant up-regulation of polycomb proteins contribute
to miR-31 down-regulation epigenetically leading to activation
of NF-κB and apoptosis resistance in ATL cells (Yamagishi et al.,
2012). Furthermore, more than 20 cellular proteins have been
reported to interact with Tax, including a number of cytoplasmic
proteins, such as MEKK1, MAD1, CBP, RelA, and IκB kinase sub-
units, as well as other nuclear proteins that are not found in Tax
Speckled Structures (TSS), including p16INK4a and p15INK4b (Jin
et al., 1998; Yin et al., 1998; Xiao et al., 2000; Azran et al., 2005).
Interactions of Tax with these proteins have profound effects on
normal host cell processes and in many cases have been shown to
be essential for or to enhance cellular transformation.
Among the properties of Tax, activation of the NF-κB path-
way plays a crucial role in the proliferation and transformation of
HTLV-1-infected T cells (Yamaoka et al., 1996; Robek and Ratner,
1999). In unstimulated cells, NF-κB is found in an inactive cytoso-
lic complex, associated with IκB. Upon cell stimulation, the IκB
proteins are phosphorylated by the IκB kinase (IKK) complex,
then ubiquitylated and subsequently degraded by the protea-
some. Consequently, RelA-containing NF-κB proteins translocate
to the nucleus, bind speciﬁc promoters, and activate NF-κB-
dependent gene transcription (Li and Gaynor, 2000). Tax acts
at multiple levels to initiate and maintain a permanent NF-κB
activation (reviewed in Geleziunas et al., 1998; Sun et al., 2000;
Jeang et al., 2004). A critical step is the recruitment of Tax to the
IKK-γ regulatory component of the IKK complex (Yamaoka et al.,
1998). Tax/IKKγ association leads to activation of the IKKα and
IKKβ kinases resulting in IκB phosphorylation, ubiquitylation,
and proteasomal degradation. The precise subcellular localiza-
tion where these events occur and their molecular requirements
remain largely unknown. We and others recently demonstrated
thatNF-κBactivation is dependent onTaxpost-translationalmod-
iﬁcations, namely ubiquitylation and sumoylation (Lamsoul et al.,
2005; Nasr et al., 2006; Kfoury et al., 2008,2011,2012),which result
in the activation of the IKK complex, phosphorylation of the NF-
κB inhibitor IκB, ultimately resulting in the nuclear translocation
of the active NF-κB subunits and activation of NF-κB-dependent
genes (reviewed in Kfoury et al., 2005, 2012). In addition, Pelo-
ponese et al. (2004) reported that ubiquitin addition modiﬁes Tax
in a proteasome-independent manner from an active to a less-
active transcriptional form. Finally, Tax subcellular distribution
and its interaction with cellular proteins respond dynamically to
cellular stress (Gatza and Marriott, 2006).
Altogether, these multiple activities of Tax cooperate to pro-
mote infected T-cell proliferation, generate cellular defects and
lead to subsequent transformation. This oncogenic potential of
Tax was demonstrated through its ability to transform a rat ﬁbrob-
last cell line (Matsumoto et al., 1997) and immortalize primary T
cells in vitro (Grassmann et al., 1992).
Tax TRANSGENIC MICE MODELS
Tax in transgenic mice models is sufﬁcient to cause oncogenesis.
However, leukemia and lymphoma are rare. The ﬁrst transgenic
mice expressing the HTLV-1 tax gene (originally called HTLV-
1 tat when mice were produced) under the control of the LTR
promoter [Tg (HIV-tat) 6-2Gja] developed multicentric mes-
enchymal tumors of the nose, ear,mouth, tail, and foot (Nerenberg
et al., 1987). These tumors were characterized by a typical spin-
dle cell component with inﬁltration of granulocytes. Although
this transgenic system is not appropriate for the study of ATL, it
proved that the tax gene encodes an oncoprotein. In addition to
the mesenchymal tumors described above, these transgenic mice
developed a disease characterized by degeneration of oxidative
muscle ﬁbers. As such, this transgenic mouse helped to under-
stand some aspects of HTLV-1-associated myopathies (Nerenberg
and Wiley, 1989). LTR-tax mice showed skeletal abnormalities.
Bones were grossly thicker and more fragile, whereas histologi-
cally they exhibited high bone turnover characterized by increases
in osteoclasts and osteoblasts (Ruddle et al., 1993). Combining the
LTR-tax mice with LTR-βgal (β galactosidase) mice generated a
bitransgenic mouse in which the transactivator protein acts on the
LTR to increase expression of βgal. The enzyme was detected in
bone,muscle, cartilage, exocrine glands, andmesenchymal tumors
(Benvenisty et al., 1992). Recently, Swaims et al. (2010) focused on
the role of HTLV-1 expression in chronically infected CD4+ T cells
using LTR-Tax transgenic mice. In this system, immune activated
Tax-expressing CD4+ T cells express characteristics of several dif-
ferent CD4+ T cell subtypes, suggesting that HTLV-1 Tax induces
changes in the normal pattern of CD4+ subtype speciﬁcation
(Kress et al., 2011).
Several transgenic C57/CBA mouse strains were generated
with tax gene under the regulatory control of CD-3ε promoter
enhancer sequence designed to target expression to leukocytes.
These mice developed mesenchymal tumors at wound sites as well
as mammary and salivary adenomas (Hall et al., 1998). Another
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model of Tax transgenics was developed in C57BL/6TgN mice
(huGMZBTax) under the control of the granzyme B promoter.
In this model, Tax expression was restricted to CD4+, CD8+,
NK cells, and lymphokine-activated killer cells (Grossman et al.,
1995). These mice exhibit a large granular lymphocytic (LGL)
leukemia and neutrophilic dominated inﬂammation at sites of
trauma admixed with LGL leukemic cells. These mice also devel-
oped splenomegaly, lymphadenopathy, and masses on the ears,
legs, and tail (Grossman et al., 1995). As in ATL patients, these
mice had malignant hypercalcemia and osteolytic bone lesions
associated with metastasis (Gao et al., 2005). This model was also
used to study the contribution of p53 inactivation to Tax-mediated
tumorigenesis (Portis et al., 2001). Primary Tax-induced tumors
and tumor-derived cell lines exhibited functional inactivation of
the p53 apoptotic pathway and were resistant to an apoptosis-
inducing stimulus. In contrast, p53 mutations in tumors were
found to be associated with secondary organ inﬁltration. Fur-
thermore, mating Tax transgenic mice with p53-deﬁcient mice
demonstrated minimal acceleration in initial tumor formation,
but signiﬁcantly accelerated disease progression and death in mice
heterozygous for p53 suggesting that functional inactivation of
p53 by HTLV-1 Tax, is not critical for initial tumor formation, but
contributes to late-stage tumor progression (Portis et al., 2001).
Using the same transgenic model, Rauch et al. (2009) reported
that Tax expression in IL-15 knockout mice led to the develop-
ment of larger and more aggressive tumors, suggesting caution
against IL-15 blockade as an ATL therapy (Martin et al., 2011).
An advantageous model to study the role of inﬂammation and
its relationship with tumor development was obtained when the
C57BL/6TgN (huGMZBTax) were crossed with an IFN-γ knock-
out strain. The obtainedmousemodel showed an enhanced rate of
lesion development (Mitra-Kaushik et al., 2004). More exploita-
tions were done on imaging tumor engraftment in vivo. Indeed,
Rauch et al. (2009) evaluated Tax-mediated activation of luciferase
in LTR-luciferase (LTR-LUC) mice [C57BL/6TgN(LtrLuc)] reﬁn-
ing the C57BL/6TgN mouse model. They reported that micro-
scopic intraepithelial lesions precede the onset of peripheral
subcutaneous tumors and that Tax is sufﬁcient for inducing
tumors. These results suggest that the viral oncoprotein acti-
vates lymphocytes to cause NK/T-cell recruitment, activation, and
subsequent transformation.
In order tomore speciﬁcally target Tax expression to leukocytes,
bitransgenic doxycycline inducible mice [Tg (EmuSR-tTa) 83Bop]
were generated to speciﬁcally control expression of wild-type or
selected tax mutants in the lymphocyte compartment. This model
showed skin manifestations as in ATL patients with a fatal der-
matologic disease characterized by inﬁltration of Tax-positive T
cells into the dermis and epidermis. Addition of doxycycline (sup-
pression of Tax expression) resulted in the resolution of lesions
(Kwon et al., 2005).
Hasegawa et al. (2006) generated tax transgenic mice in which
the transgene expression was restricted to the thymus by the Lck
promoter [C57BL/6-Tg (Lck-HTLV-1 Tax)]. This mouse model
was a further conﬁrmation that Tax alone can induce leukemia
and hence represents the powerful oncogene of HTLV-1 virus.
Indeed, HTLV-1 Tax transgenic mice were generated using the lck
proximal promoter to restrict transgene expression to developing
thymocytes. Following prolonged latency periods (around 18
months), animals developed diffuse large cell lymphomas and
leukemia with clinical, pathological and immunological features
characteristic of acute ATL with characteristic ﬂower cells, and
extensive lymphomatous inﬁltration of the spleen, lymph nodes,
bone marrow, liver, kidney, and lung by malignant T lympho-
cytes highly expressing CD25 (Hasegawa et al., 2006). As in ATL
patients, mice showed marked leukocytosis, hypercalcemia, and
high level of LDH and constitutive activation of the NF-κB
pathway (Hasegawa et al., 2006; El Hajj et al., 2010).
IDENTIFICATION OF ATL STEM CELLS IN MURINE ATL
DERIVED FROM Tax TRANSGENICS
Transferring murine ATL splenic cells derived from Tax trans-
genics (Hasegawa et al., 2006) to NOD/SCID mice allowed the
identiﬁcation of the ﬁrst candidate ATL stem cells in a side pop-
ulation (0.06%), which overlapped with a minor population of
CD38−/CD71−/CD117+ cells (0.03%). In addition, lymphoma
and ATL stem cells could also be demonstrated in the bone
marrow and in both osteoblastic and vascular niches. In these
ATL stem cells, Tax, Notch1, and Bmi1 expression was down-
regulated, suggesting that they were derived from Pro-T cells
or early hematopoietic progenitor cells (Yamazaki et al., 2009).
Using the same Tax transgenic model, Kawaguchi et al. (2009)
demonstrated thatAMD3100, aCXCR4antagonist, inhibited inﬁl-
tration of lymphomatous cells into liver and lung tissues in vivo.
Their results demonstrated the involvement of the stromal cell-
derived factor-1α (SDF-1α) and its receptor CXCR4 interaction
as one mechanism of leukemic cell migration and this may pro-
vide a novel target as part of combination therapy for ATL. The
same tax transgenic mouse model generated by Hasegawa et al.
(2006) was used in an interesting study using a bioinformatics
approach where Suzuki et al. (1993) could identify in a com-
parative proteomic analysis, proteins differentially expressed in
Tax induced lymphoma (Martin et al., 2011). Strikingly, among
the more than 700 proteins detected, levels of 53 proteins were
increased in stem cells, including one membrane protein, which
might potentially serve as a new target of antibody based therapy
(Martin et al., 2011).
Tax TRANSGENICS AS A PLATEFORM TO TEST
TARGETED THERAPY OF ATL
In addition to the xenograft humanized mouse models, transgenic
mice provided insights to clinicians before the development of
phase I clinical trials. They were used in many translational stud-
ies to examine the effect of different targeted therapies of ATL
(summarized in Zimmerman et al., 2010).
Adult T-cell leukemia/lymphoma is resistant to chemotherapy
and carries a very poor prognosis (reviewed in Shimoyama, 1991;
Bazarbachi et al., 2004). Multiple small studies using AZT and
IFN showed response in ATL patients. A worldwide meta-analysis
recently showed that antiviral therapy signiﬁcantly increased 5-
year survival of ATL patients from 20 to 50% (Bazarbachi et al.,
2010). Unfortunately, most patients eventually relapse, which
underlines the need for new therapeutic approaches. Using an
in vitro model of ATL derived cell lines and freshly isolated
ATL leukemic cells, Bazarbachi et al. (1999) showed that arsenic
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trioxide synergizes with IFN to selectively induce G1 arrest
and apoptosis in ATL cells. This combination yielded promis-
ing clinical results in relapsed/refractory ATL patients (Hermine
et al., 2004). Critically, this drastic phenotype was associated
to rapid proteasome-mediated Tax degradation upon exposure
to the drug combination (El-Sabban et al., 2000; Nasr et al.,
2003). Promising results were recently obtained in de novo ATL
patients treated with arsenic trioxide, IFN, and AZT, with 100%
response rate including 70% complete remission rate (Kchour
et al., 2009).
El Hajj et al. (2010) recently reported that the combination of
arsenic trioxide and IFN cures Tax-driven murine ATLs through
selective targeting of leukemia initiating cell (LIC) activity. We
used a transplantation model of murine ATL by transferring
murine ATL splenic cells derived from Tax transgenics (Hasegawa
et al., 2006) to NOD/SCID mice. These mice develop ATL-like dis-
easemanifested by diffuse large cell lymphomas and leukemiawith
clinical, pathological, and immunological features characteristic of
acute ATL with typical ﬂower cells, and extensive lymphomatous
inﬁltration of the spleen, lymph nodes, bone marrow, liver, kid-
ney, and lung bymalignant T lymphocytes highly expressingCD25
(Hasegawa et al., 2006). As in ATL patients, mice showed marked
leukocytosis, hypercalcemia, and high level of LDH and consti-
tutive activation of the NF-κB pathway (Hasegawa et al., 2006;
El Hajj et al., 2010). Unexpectedly, ATL cells did not respond
to arsenic and IFN by apoptosis and/or cell cycle arrest in vivo
and therefore this regimen does not induce rapid tumor regres-
sion or massive cell death in treated animals. Importantly, on
the other hand, this combination therapy used in primary mice
immediately reduces leukemia transplantation into untreated sec-
ondary recipients and totally abrogates leukemia transplantation
into untreated tertiary recipients. In other words, the primary
tumor continues to grow and only exhausts much later, due to the
speciﬁc targeting of LIC activity. Adding the proteasome inhibitor
bortezomib essentially blocks the degradation of Tax triggered by
the arsenic/IFN combination, and eliminates the enhancement
of survival in secondary and tertiary recipients. This reversal of
ATL LIC eradication by proteasome inhibition is a signiﬁcant
indication that ATL cells are addicted to continuous Tax expres-
sion for their LIC activity (stemness) but not for their short-term
tumor growth.
Since the action of the arsenic/IFN combination is very speciﬁc
to both HTLV-1-infected cells and Tax-driven murine leukemia,
it is most likely that therapy-induced loss of the driving oncogene
underlies responsiveness to therapy.
HBZ TRANSGENICS DEVELOP TUMORS BUT NOT ATL
Despite the fact that the expression of Tax is frequently dis-
rupted in ATL (Matsuoka and Jeang, 2007), the HTLV-1 bZIP
factor (HBZ) gene, which is encoded by the minus strand of
the HTLV-1 genome (Larocca et al., 1989; Gaudray et al., 2002),
is transcribed in all ATL cases (Satou et al., 2006). The HBZ
gene product promotes the proliferation of ATL cells (Satou et al.,
2006; Arnold et al., 2008). Furthermore, HBZ mRNA expression
in HAM/TSP patients was well correlated with disease severity
(Saito et al., 2009). Satou et al. (2011) generated transgenic mice
containing the HBZ gene under control of a murine CD4-speciﬁc
promoter/enhancer/silencer (HBZ-Tg mice). HBZ-Tg mice spon-
taneously developed systemicdermatitis, alveolitis, and lymphoma
as they aged and expressed the HBZ gene in all murine CD4+
cells. This group demonstrated that transgenic expression of
HBZ in CD4+ T cells induced T-cell lymphomas and systemic
inﬂammation in mice. Importantly, whereas human ATL cells and
murine ATL cells derived from tax transgenics displayed constitu-
tive activation of the NF-κB pathway, NF-κB was not activated in
T-cell lymphomas observed in HBZ transgenics, hence demon-
strating that HBZ alone cannot maintain the ATL phenotype
in vivo
Since the immune system plays a major role in HAM/TSP
progression and since HBZ mRNA expression was correlated
with disease severity (Saito et al., 2009), Satou et al. (2011) used
the HBZ transgenic mouse model to study the CD4+Foxp3+
Treg population speciﬁcally that ATL cells were shown to func-
tionally and phenotypically resemble Foxp3+CD25+CD4+ Treg
cells, which control immune responses against self- and non-
self-antigen (Sakaguchi et al., 2008). In HBZ-transgenic mice,
CD4+Foxp3+ Treg cells and effector/memory CD4+ T cells
increased in vivo. As a mechanism of increased Treg cells, HBZ
expression directly induced Foxp3 gene transcription in T cells.
However, the increased CD4+Foxp3+ Treg cells in HBZ trans-
genicmicewere functionally impairedwhile their proliferationwas
enhanced (Satou et al., 2011). To further investigate the expression
of Foxp3, Taguchi et al. used the HBZ transgenics to investigate
the production of cytokines and they provided data to support
the concept that altered Foxp3 expression in iTreg cells might
result in systemic inﬂammation (Matsuoka and Green, 2009;
Martin et al., 2011).
CONCLUSION
Collectively, advances in the development of animal models have
extended opportunities to better understand the biology of HTLV-
1-related diseases. Rising from naturally infected to genetically
engineered models, these animals provided new insights on the
biology of HTLV-1 and related viruses. They allowed a better
understanding of the multiple genetic, epigenetic, and cellu-
lar aberrations that occur during the progression of leukemia
in humans, cattle, and monkeys. They highlighted the immune
response against these viruses providing new insights on the
potential development of vaccines. Humanized mice models
using immunocompromised animals pointed to the importance
of hematopoietic stem cells in HTLV-1 infection andATL develop-
ment. Genetically engineered mice demonstrated that Tax triggers
ATLdevelopment, allowed the identiﬁcation of potentialATL stem
cells and the preclinical development of targeted therapies such as
monoclonal antibodies or the combination of arsenic trioxide and
IFN-α.
Using the translation of knowledge from the laboratory bench
to appropriate animal models and subsequently to patients pro-
vides hope for the prevention, and/or development of targeted and
efﬁcacious treatments against a highly refractory neoplasm such
as ATL. For the ﬁrst time, a proposed drug regimen showed an
efﬁcient and speciﬁc targeting of the leukemia initiating cells and
was translated into an excellent responsiveness of human patients
yielding to improved survival and potential cure of ATL.
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